Suggested remit: To appraise the clinical and cost effectiveness of treprostinil sodium within its marketing authorisation for treating chronic thromboembolic pulmonary hypertension.
Status Awaiting development
Decision None selected
Process STA 2018
ID number 3926

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
05 November 2021 - 03 December 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
01 December 2021 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of treprostinil sodium for treating symptomatic chronic thromboembolic pulmonary hypertension. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this appraisal. Following an update from the company that markets treprostinil sodium, NICE will not be progressing with the scoping exercise at this time. The consultation on the draft scope will now close and the workshop arranged for Monday 20 December 2021 has been cancelled. Please accept our apologies for any inconvenience.

For further information on our processes and methods, please see our CHTE processes and methods manual